Description: Tryptamine Therapeutics Limited, a clinical-stage pharmaceutical development company, focuses on developing synthetic psilocybin-related molecules in Australia, Canada, Switzerland, and the United States. The company's lead program candidate TRP-8803, a proprietary formulation of IV-infused psilocin that completed Phase 2 clinical trial for the treatment of binge eating disorder, fibromyalgia, irritable bowel syndrome, abdominal pain, and visceral tenderness. It is also involved in the development of TRP-8802, a synthetic and oral psilocybin, currently under phase 2a clinical stager for the treatment of binge eating, as well as under phase 2 clinical stage for the treatment of fibromyalgia, and irritable bowel syndrome. The company was founded in 2019 and is based in Camberwell, Australia.
Home Page: www.tryptherapeutics.com
697 Burke Road
Camberwell,
VIC
3124
Australia
Phone:
61 3 9092 0475
Officers
| Name | Title |
|---|---|
| Mr. Jason Carroll | MD, CEO & Executive Director |
| Dr. James P. Gilligan MSIB, Ph.D. | President & Chief Scientific Officer |
| Dr. William James Garner M.D., M.P.H., MPH | Founder & MD |
| Mr. Hamish George B.Com., C.A. | Chief Financial Officer |
| Dr. Michael H. Silverman B.Sc., F.A.C.P., FACR, M.B.A., M.D. | Chief Medical Officer |
| Mr. David James Franks BEc, C.A., F Fin, J.P. | Company Secretary |
Exchange: PINK
Country: US : United States of America
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | |
| Fiscal Year End: | June |
| Full Time Employees: | 0 |